

# ImmunoTools IT-Box-139 Award 2012



**Elisabeth Maritschnegg**

PhD Supervisor: Prof. Dr. Robert Zeillinger

Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria

## Blood as diagnostic tool for ovarian cancer

We have developed a 13 gene-signature derived from immune cells, capable of discriminating healthy woman from woman with epithelial ovarian cancer (EOC) with specificities and sensitivities of over 95%. EOC is one of the deadliest malignancy in woman, mainly due to late diagnosis. A test for earlier diagnosis could help to improve overall survival tremendously.

The immune cell fraction – which was used for gene signature development – was derived from a two-step gradient procedure; but we do not know exactly which cells are in there: What we know is, that it consists mainly of granulocytes and some lymphocytes.

In addition, we plan to further subfractionate this fraction, mainly to improve the discriminative power of our signature.

We will use the antibodies from ImmunoTools to determine the definite composition of our immune cell fraction and further obtained immune cell fractions. Therefore we would need panels to define leukocytes (mainly granulocytes) and lymphocytes (mainly monocytes and T-cells).

Furhter panels would help to define T-cell subfractions, B-cells, NK cells, etc...

Granulocytes: CD16-FITC (pan), CD18-PE (activated), CD44-APC (eosinophils)  
CD16-FITC (pan), CD13-PE (basophils)

Monocytes: CD3-PE/Dy647, CD14-PE, CD40-APC, CD16-FITC  
CD3-PE/Dy647, CD14-PE, CD40-APC, HLA-DR-FITC

T-cells: CD3-PE/Dy647, CD4-PE, CD8-FITC

## ImmunoTools IT-Box-139 for Elisabeth Maritschnegg includes 100 antibodies

**FITC** - conjugated anti-human CD1a, CD3, CD4, CD5, CD6, CD7, CD8, CD14, CD15, CD16, CD19, CD21, CD25, CD29, CD35, CD36, CD41a, CD42b, CD45, CD45RA, CD45RB, CD45RO, CD49d, CD53, CD57, CD61, CD63, CD80, CD86, HLA-DR, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

**PE** - conjugated anti-human CD3, CD4, CD8, CD11b, CD15, CD14, CD18, CD19, CD20, CD21, CD22, CD31, CD33, CD38, CD40, CD45, CD45RB, CD50, CD52, CD56, CD58, CD62p, CD72, CD95, CD105, CD147, CD177, CD235a, HLA-ABC, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

**PE/Dy647** -tandem conjugated anti-human CD3, CD4, CD8, CD14, CD19, CD20, CD25, CD54

**APC** -conjugated anti-human CD2, CD3, CD4, CD8, CD10, CD11a, CD11c, CD14, CD16, CD27, CD37, CD42b, CD44, CD45, CD59, CD62L, CD69, CD71, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

[DETAILS](#)